CordenPharma Investing $981 M To Expand Peptide Mfg

CordenPharma, a CDMO of drug substances and drug products, has announced an investment of more than EUR 900 million ($981 million) over the next three years to expand peptide manufacturing at its site in Colorado and in Europe. The expansions cover both existing facilities and new construction. The investment represents the single largest investment in the company to date.   

The Colorado site’s expansion will target additional large-scale peptide manufacturing capacity to meet increasing demand of glucagon-like peptide-1 (GLP-1) peptides, resulting from multiple long-term manufacturing contracts totaling approximately EUR 3 billion ($3.3 billion), with potential upsides. 

In Europe, CordenPharma will construct a greenfield site for small- to large-scale peptide development and manufacturing, integrated within its global facility network. 

Source: CordenPharma